Transcripta Bio is a company that focuses on drug development at a size and pace never seen before, with a lower risk.
Transcripta Bio has raised $24.0M in total funding. The most recent round was Series A. The last funding was announced in July 2026.
Transcripta Bio's investors include Gaingels, Mayo Clinic, BlueYard Capital, Jazz Venture Partners, Omnimed Capital.
Transcripta Bio is headquartered in Palo Alto, United States.
Transcripta Bio is a company that focuses on drug development at a size and pace never seen before, with a lower risk.
Transcripta Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Transcripta Bio — Funding & Investors." VCBacked, July 22, 2026, https://www.vcbacked.co/company/transcripta-bio. Accessed November 12, 2026.
VCBacked. (2026). Transcripta Bio — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/transcripta-bio
{{cite web |title=Transcripta Bio — Funding & Investors |url=https://www.vcbacked.co/company/transcripta-bio |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Transcripta Bio? Request a listing update